TXNRD1 and breast cancer: Auranofin, a TrxR1 inhibitor, leads to oxidative stress-induced lethality and apoptosis in cancers including chronic myeloid leukemia [19], chronic lymphocytic leukemia [43], prostate cancer [44], breast cancer [45], and acute leukemia [46].